Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2000037115Phase 4Not yet recruiting
Phase 4, randomised, open-label trial of liraglutide in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Urinary albumin/creatinine ratio. Planned start Oct 2020; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2000037115.